News

Hillary Clinton will deliver a keynote address at the 2014 BIO International Convention in San Diego.

FDA and EMA release a draft joint proposal on the development of new drugs to treat Gaucher disease in children.

FDA clarifies stability data recommendations for abbreviated new drug applications.

Draft guidance addresses the use of clinical pharmacology studies to determine biosimilarity of biologics.

Eurofins Scientific will acquire ViraCor-IBT Laboratories for $255 million.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

Cumberland Pharmaceuticals and Gloria Pharmaceuticals invest $1 million each in Cumberland Emerging Technologies.

Boehringer Ingelheim and Connexios Life Sciences announce global research collaboration agreement for AMPK agonists.

The Pediatric Clinical Research Group initiative expands to include pediatric research sites.

A multi-institutional effort will fight pediatric leukemia and neuroblastoma.

FDA releases draft guidance on the development of drugs to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia.

The Fogarty International Center, a component of the US NIH, calls for a focus on noncommunicable diseases and implementing science in low-resource settings.

WHO report provides a comprehensive picture of antibiotic resistance and suggests strategies to fight resistance.

AstraZeneca rejects $106 billion offer; Pfizer states its case for the merger with British government.

Gallus BioPharmaceuticals enters a cell line optimization and manufacturing agreement with Omni Bio Pharmaceutical.

USP releases new and revised standards for organic impurities in medicines for public comment.

Agenus and Merck work together to advance immune-oncology programs.

Allergy Therapeutics announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.

The European Medicines Agency's Annual Report highlights the agency's drug approvals, projects, and initiatives for 2013.

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.

ISPE drug shortage prevention plan to address organizational strategies, manufacturing and quality systems, and supply chain quality.

Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.

Research reveals that proteins involved in autism interact with many more partners than previously known.

Portfolio swaps between Novartis and GSK involve oncology, vaccines, and consumer products.

University of Michigan study demonstrates how a Silly Putty ingredient could advance stem cell therapies.

Eli Lilly will acquire Novartis Animal Health for approximately $5.4 billion.

Genetic evidence supports role of APOBEC gene family in cancer development.